The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study

被引：0
|
作者：
Adam M Deane
Marianne J Chapman
Robert JL Fraser
Carly M Burgstad
Laura K Besanko
Michael Horowitz
机构：
[1] University of Adelaide,, Discipline of Anaesthesia and Intensive Care
[2] Royal Adelaide Hospital,Department of Intensive Care
[3] Repatriation General Hospital,Investigation and Procedures Unit
[4] University of Adelaide,Discipline of Medicine
[5] Royal Adelaide Hospital,Department of Gastroenterology
来源：
Critical Care | / 13卷
关键词：
Glucagon; Enteral Feeding; Glucagon Concentration; Glycaemic Response; Royal Adelaide Hospital;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study
    Hellstrom, P. M.
    Hein, J.
    Bytzer, P.
    Bjornsson, E.
    Kristensen, J.
    Schambye, H.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 29 (02) : 198 - 206
  • [22] Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes-a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study
    Dejgaard, Thomas Fremming
    Knop, Filip Krag
    Tarnow, Lise
    Frandsen, Christian Seerup
    Hansen, Tanja Stenbaek
    Almdal, Thomas
    Holst, Jens Juul
    Madsbad, Sten
    Andersen, Henrik Ullits
    BMJ OPEN, 2015, 5 (04):
  • [23] Effect of synbiotic therapy on the incidence of ventilator associated pneumonia in critically ill patients: a randomised, double-blind, placebo-controlled trial
    Knight, David J. W.
    Gardiner, Dale
    Banks, Amanda
    Snape, Susan E.
    Weston, Vivienne C.
    Bengmark, Stig
    Girling, Keith J.
    INTENSIVE CARE MEDICINE, 2009, 35 (05) : 854 - 861
  • [24] Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study
    Preman Kumarathurai
    Christian Anholm
    Olav W. Nielsen
    Ole P. Kristiansen
    Jens Mølvig
    Sten Madsbad
    Steen B. Haugaard
    Ahmad Sajadieh
    Cardiovascular Diabetology, 15
  • [25] Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study
    Nino, Antonio
    Okuda, Inaha
    Wilson, Timothy H.
    Yue, Lynn
    Nakajima, Hiromu
    Tsuboi, Maho
    Carr, Molly C.
    Seino, Yutaka
    JOURNAL OF DIABETES INVESTIGATION, 2018, 9 (03): : 558 - 566
  • [26] Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study
    Kumarathurai, Preman
    Anholm, Christian
    Nielsen, Olav W.
    Kristiansen, Ole P.
    Molvig, Jens
    Madsbad, Sten
    Haugaard, Steen B.
    Sajadieh, Ahmad
    CARDIOVASCULAR DIABETOLOGY, 2016, 15
  • [27] Effect of synbiotic therapy on the incidence of ventilator associated pneumonia in critically ill patients: a randomised, double-blind, placebo-controlled trial
    David J. W. Knight
    Dale Gardiner
    Amanda Banks
    Susan E. Snape
    Vivienne C. Weston
    Stig Bengmark
    Keith J. Girling
    Intensive Care Medicine, 2009, 35
  • [28] AKL1, a botanical mixture for the treatment of asthma: A randomised, double-blind, placebo-controlled, cross-over study
    Thomas M.
    Sheran J.
    Smith N.
    Fonseca S.
    Lee A.J.
    BMC Pulmonary Medicine, 7 (1)
  • [29] The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study
    Umpierrez, G. E.
    Blevins, T.
    Rosenstock, J.
    Cheng, C.
    Anderson, J. H.
    Bastyr, E. J., III
    DIABETES OBESITY & METABOLISM, 2011, 13 (05): : 418 - 425
  • [30] EFFECT OF DIPEPTIDYL PEPTIDASE-IV INHIBITOR TREATMENT ON POST-PRANDIAL GLUCAGON AND GLUCAGON-LIKE PEPTIDE-1 LEVELS IN PATIENTS WITH TYPE 1 DIABETES: AN INVESTIGATOR-INITIATED, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL
    Moser, E. G.
    Snell-Bergeon, J.
    Garg, S.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2012, 60 (01) : 138 - 139
12345